Latest News and Press Releases

Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with...

Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies Webcast to be held on July 10, 2018 at 8:00 AM...

- Trial supports Actinium’s strategic expansion of its CD33 program into novel combinations that can lead to increased use of bone marrow transplants and expand the addressable patient population for...

- Dr. Vijay Reddy joins Actinium with over 20 years of bone marrow transplant clinical experience including extensive product development experience at Pharmacyclics, an AbbVie Company, Medimmune and...

Clinical trial to be conducted by the Medical College of Wisconsin as an investigator initiated trial led by Dr. Sameem Abedin in collaboration with Dr. Ehab Atallah  Combination trial expands...

NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 30th...

• Conference call to be held on Tuesday, February 13th, 2018 at 4:30 PM ET to discuss planned Phase 1 clinical trial with Dr. Ehab Atallah • New trial represents expansion of Actinium’s CD33 program...

- Mr. Kapur joins Actinium with more than two decades of biopharmaceutical commercial experience at Johnson & Johnson, BAXALTA and Bristol-Myers Squibb  - Global leader with deep expertise in...

- Actimab-A plus CLAG-M further expands Actinium’s CD33 program and addressable patient population of Actimab-A  - Combination aligns with Actinium’s focus on improving bone marrow transplant access...

NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it will be attending and presenting at the BIO CEO...